Elsevier MDL releases major DiscoveryGate® upgrade to boost research productivity

SAN LEANDRO, CA - June 13, 2005 - Elsevier MDL is pleased to announce the release of an enhanced version of DiscoveryGate, the company's highly acclaimed content platform for chemistry and life sciences research. Leveraging MDL® Isentris® technology, the new DiscoveryGate provides improved performance and usability-helping researchers rapidly find critical scientific information from a broad array of sources.

"With more than 300 customers and thousands of users, DiscoveryGate is already a significant success in the global pharma and biotech R&D arenas," said Elsevier MDL CEO Lars Barfod. "Customer requirements for improved productivity played a key role in this major upgrade, which provides faster responses to complex queries, improved usability and easy installation and maintenance. DiscoveryGate continues to demonstrate the impressive enterprise-scale capabilities of the MDL Isentris development framework for science."

DiscoveryGate ( www.discoverygate.com) integrates information from 25 chemistry and pharmacology databases on a single hosted platform, providing direct links to the primary literature and integration with customers' internal systems.

For any given search, the platform provides comprehensive results in the context of the original query. For example, researchers querying specific reaction databases can use new "Also Found In" links to simultaneously retrieve related information from other chemistry, molecular biology, bioactivity, metabolism/toxicology, chemical sourcing and synthetic methodology databases.

The database links extend to important new sources including the xPharm® database, which is the world's largest pharmacological reference work, and MDL® Patent Chemistry Database, an extensive new reaction and factual database for scientists in chemistry and the life sciences.

About Elsevier MDL

Elsevier MDL provides informatics, database and workflow solutions that accelerate successful life sciences R&D by improving the speed and quality of scientists' decision making. Researchers around the world depend on Elsevier MDL for innovative and reliable discovery informatics software solutions and services augmented by 400 Elsevier chemistry and life sciences journals and related products. For more information, visit www.mdl.com. Elsevier is a world-leading publisher of scientific, technical and medical information products and services. For more information visit www.elsevier.com.

Elsevier is part of Reed Elsevier Group plc, a world-leading publisher and information provider. Reed Elsevier's ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange). For more information, visit www.reedelsevier.com.

About Elsevier
Elsevier is a global information analytics business that helps scientists and clinicians to find new answers, reshape human knowledge, and tackle the most urgent human crises. For 140 years, we have partnered with the research world to curate and verify scientific knowledge. Today, we’re committed to bringing that rigor to a new generation of platforms. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support, and professional education; including ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, 39,000 e-book titles and many iconic reference works, including Gray's Anatomy. Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. www.elsevier.com


Dr. Phil McHale

Elsevier MDL

VP, Market and Corporate Communications

Phone: (510) 357-2222 ext. 3541



MDL, Isentris and DiscoveryGate are registered trademarks of MDL Information Systems, Inc. ('Elsevier MDL') in the United States and/or other countries. All rights reserved.